DropsMRP Under Process
Official PMBI MRP is being updated for catalog code 2507.
Locate Jan Aushadhi KendraClinical Overview
Ceruminolytic Ear Drop formulation combining Paradichlorobenzene (2%), Chlorbutol (5%), Turpentine Oil (15%), and Lidocaine (2%). Paradichlorobenzene hydrates and dissolves hard impacted cerumen; turpentine oil acts as a counter-irritant and cerumen liquefier; chlorbutol provides mild antibacterial and antifungal preservation; and lidocaine relieves localized ear canal pain and tension. Indicated for softening, loosening, and removal of hardened, impacted ear wax.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Tilt head sideways and instill 4 to 5 drops into the affected ear canal. Retain drops for 5 to 10 minutes using a small cotton ball plugged gently at the ear meatus. Repeat twice daily for 2 to 3 days prior to ear irrigation or syringing by a physician.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Local transient tingling, mild warmth, ear fullness. Rare/Severe: Ear canal irritation and allergic contact dermatitis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in perforated tympanic membrane, acute otitis media, or active ear drainage. Do not use cotton swabs (Q-tips) deep inside the ear canal, as they push softened wax deeper against the eardrum.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or ophthalmic treatment recommendations. Always consult a registered ophthalmologist or ENT specialist before initiating, changing, or instilling any ophthalmic or otic medication.
Beclomethasone 0.025% and Neomycin 0.5% Cream
Beclomethasone 0.025% and Neomycin 0.5% Cream is an evidence-based dermatological formulation. It acts by delivering targeted active therapeutic ingredients to cutaneous lesions to relieve skin pathology, restore barrier integrity, and manage dermatoses.
Betamethasone Valerate 0.1% and Neomycin Sulfate 0.5% Cream
Betamethasone Valerate / Dipropionate is a potent topical corticosteroid on the WHO Model List of Essential Medicines. It suppresses cutaneous inflammatory edema, erythema, and pruritus in eczema, psoriasis, and severe contact dermatitis. Often formulated in combination with Fusidic Acid, Gentamicin, or Miconazole to treat secondarily infected dermatoses.
Betamethasone Valerate 0.12% and Clioquinol 3% Cream
Betamethasone Valerate / Dipropionate is a potent topical corticosteroid on the WHO Model List of Essential Medicines. It suppresses cutaneous inflammatory edema, erythema, and pruritus in eczema, psoriasis, and severe contact dermatitis. Often formulated in combination with Fusidic Acid, Gentamicin, or Miconazole to treat secondarily infected dermatoses.
Betamethasone Sodium Phosphate Tablets 0.5 mg
Betamethasone (Sodium Phosphate Tablets IP 0.5mg) is a potent, long-acting synthetic glucocorticoid on the WHO Model List of Essential Medicines. Structurally the 16-beta isomer of dexamethasone, it provides potent anti-inflammatory action with zero mineralocorticoid effect and readily crosses the placenta to stimulate fetal type II pneumocyte maturation and surfactant production. Indicated for antenatal prophylaxis of neonatal respiratory distress syndrome (RDS) and intraventricular hemorrhage in preterm labor, severe rheumatoid arthritis, angioedema, and dermatological autoimmune flares.